Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Interest Expenses (2020 - 2024)

Whitehawk Therapeutics (WHWK) has disclosed Interest Expenses for 4 consecutive years, with $38000.0 as the latest value for Q3 2024.

  • On a quarterly basis, Interest Expenses fell 34.48% to $38000.0 in Q3 2024 year-over-year; TTM through Jun 2025 was $38000.0, a 83.55% decrease, with the full-year FY2024 number at $154000.0, down 33.33% from a year prior.
  • Interest Expenses was $38000.0 for Q3 2024 at Whitehawk Therapeutics, down from $58000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $227000.0 in Q2 2021 to a low of $38000.0 in Q3 2024.
  • A 4-year average of $86866.7 and a median of $58000.0 in 2022 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: plummeted 74.89% in 2022, then grew 1.75% in 2023.
  • Whitehawk Therapeutics' Interest Expenses stood at $80000.0 in 2021, then decreased by 28.75% to $57000.0 in 2022, then changed by 0.0% to $57000.0 in 2023, then crashed by 33.33% to $38000.0 in 2024.
  • Per Business Quant, the three most recent readings for WHWK's Interest Expenses are $38000.0 (Q3 2024), $58000.0 (Q2 2024), and $58000.0 (Q1 2024).